SKLB-163

Description: SKLB-163 acts by downregulating RhoGDI, activating JNK-1 signaling pathway and caspase-3, and reducing phosphorylated Akt and p44/42 MAPK. Target: Rho, Akt, Caspase, MAPK, JNK. Smiles: S(CC(NCC1=CC=CC=C1)=O)C2=NC=3C(S2)=CC(NC(CCl)=O)=CC3. References: Kohno K, Ohashi E, et al. Anti-inflammatory effects of adenosine N1-oxide. J Inflamm (Lond). 2015 Jan 20,12(1):2.